Healthcare provider profile · identity verified

Mala Ashok, MD

Family Practice · WEBSTER, NY · NPI 1619109956

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	460	117
Atorvastatin Calcium	Atorvastatin Calcium	412	136
Lisinopril	Lisinopril	237	74
Omeprazole	Omeprazole	235	72
Losartan Potassium	Losartan Potassium	234	66
Amlodipine Besylate	Amlodipine Besylate	204	66
Rosuvastatin Calcium	Rosuvastatin Calcium	183	58
Gabapentin	Gabapentin	163	39
Simvastatin	Simvastatin	159	53
Pantoprazole Sodium	Pantoprazole Sodium	121	39
Hydrochlorothiazide	Hydrochlorothiazide	117	43
Metformin Hcl	Metformin Hcl	114	32
Albuterol Sulfate Hfa	Albuterol Sulfate	109	43
Escitalopram Oxalate	Escitalopram Oxalate	108	27
Trazodone Hcl	Trazodone Hcl	108	31
Metformin Hcl Er	Metformin Hcl	101	36
Metoprolol Succinate	Metoprolol Succinate	99	27
Fluoxetine Hcl	Fluoxetine Hcl	73	18
Hydroxyzine Hcl	Hydroxyzine Hcl	73	18
Alprazolam	Alprazolam	68	23
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	68	28
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	64	16
Ozempic	Semaglutide	64	11
Tamsulosin Hcl	Tamsulosin Hcl	64	15
Pregabalin	Pregabalin	63	14
Sertraline Hcl	Sertraline Hcl	63	17
Montelukast Sodium	Montelukast Sodium	62	15
Duloxetine Hcl	Duloxetine Hcl	59	18
Eliquis	Apixaban	58	13
Metoprolol Tartrate	Metoprolol Tartrate	58	15
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	56	19
Meloxicam	Meloxicam	55	20
Atenolol	Atenolol	54	17
Fluticasone Propionate	Fluticasone Propionate	54	22
Warfarin Sodium	Warfarin Sodium	54	suppressed
Famotidine	Famotidine	53	18
Furosemide	Furosemide	52	17
Carvedilol	Carvedilol	50	11
Januvia	Sitagliptin Phosphate	48	13
Zolpidem Tartrate	Zolpidem Tartrate	47	11
Pravastatin Sodium	Pravastatin Sodium	46	15
Synthroid	Levothyroxine Sodium	45	11
Lorazepam	Lorazepam	44	16
Alendronate Sodium	Alendronate Sodium	42	suppressed
Prednisone	Prednisone	42	37
Bupropion Xl	Bupropion Hcl	39	12
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	39	suppressed
Torsemide	Torsemide	37	11
Ezetimibe	Ezetimibe	35	suppressed
Chlorthalidone	Chlorthalidone	34	14
Mirtazapine	Mirtazapine	34	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	33	26
Venlafaxine Hcl Er	Venlafaxine Hcl	33	13
Amitriptyline Hcl	Amitriptyline Hcl	31	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	11
Levetiracetam	Levetiracetam	28	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	28	suppressed
Buspirone Hcl	Buspirone Hcl	26	suppressed
Irbesartan	Irbesartan	26	suppressed
Baclofen	Baclofen	25	suppressed
Clonazepam	Clonazepam	25	12
Diazepam	Diazepam	25	suppressed
Oxycodone Hcl	Oxycodone Hcl	25	suppressed
Clopidogrel	Clopidogrel Bisulfate	24	suppressed
Azithromycin	Azithromycin	23	22
Glimepiride	Glimepiride	23	suppressed
Tramadol Hcl	Tramadol Hcl	23	suppressed
Allopurinol	Allopurinol	22	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	22	suppressed
Mometasone Furoate	Mometasone Furoate	22	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	21	13
Hydroxyzine Pamoate	Hydroxyzine Pamoate	21	suppressed
Methylprednisolone	Methylprednisolone	21	17
Propranolol Hcl	Propranolol Hcl	21	suppressed
Valacyclovir	Valacyclovir Hcl	20	12
Acyclovir	Acyclovir	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	18	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	18	suppressed
Amoxicillin	Amoxicillin	17	12
Aripiprazole	Aripiprazole	17	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	17	suppressed
Topiramate	Topiramate	17	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	15
Trulicity	Dulaglutide	16	suppressed
Celecoxib	Celecoxib	15	suppressed
Finasteride	Finasteride	15	suppressed
Larin	Norethindrone Ac/Eth Estradiol	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	14
Chlorhexidine Gluconate	Chlorhexidine Gluconate	14	suppressed
Glipizide	Glipizide	14	suppressed
Glipizide Er	Glipizide	14	suppressed
Potassium Chloride	Potassium Chloride	14	suppressed
Solifenacin Succinate	Solifenacin Succinate	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	13	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Jardiance	Empagliflozin	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Levemir Flexpen	Insulin Detemir	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error